In addition to being a metabolite of 5-FU, FdUrd (also known as floxuridine) is an FDA-approved drug for the treatment of hepatic colon metastases (2) . Moreover, the drug has activity in multiple cancers, including ovarian cancer (3) (4) (5) (6) (7) (8) (9) (10) (11) . Unlike 5-FU, however, FdUrd is generally believed to exert its antiproliferative effects primarily through the disruption of DNA replication (i.e., by inhibiting thymidylate synthase and/or causing the incorporation of 5-FU into genomic DNA) (12) . Thus, in addition to being a useful clinical agent, FdUrd is also frequently used by basic researchers as a means to specifically focus on 5-FU's DNA-directed effects. Mechanism-guided identification of novel drug combination 4 Nucleoside analogs, including 5-FU and FdUrd, disrupt dNTP levels and are incorporated into DNA, two events that stall DNA replication and activate ATR (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , an apical kinase in the ATR checkpoint signaling pathway. Activated ATR phosphorylates multiple substrates, including the kinase Chk1. Collectively, ATR and Chk1 phosphorylate substrates that promote cell survival by impeding cell cycle progression, orchestrating DNA repair, and stabilizing stalled replication forks (23) .
Notably, however, FdUrd and 5-FU also induce double-stranded DNA breaks (24, 25) , which activate the ATM signaling pathway (26) , including the ATM substrate checkpoint kinase 2 (Chk2). Like the ATR pathway, the ATM pathway promotes survival of cells with double-stranded DNA breaks by blocking cell cycle progression and mobilizing DNA repair machinery. Although both the ATR and ATM signaling pathways are activated by 5-FU and FdUrd, the roles these pathways play in regulating the survival of human tumors treated with these agents have not been explored fully.
The genomically incorporated uracil (U) and 5-FU are also targets of the base excision repair (BER) machinery (12) . In this repair pathway, non-bulky DNA lesions are first recognized and cleaved by a DNA glycosylase, producing an abasic site, which is further processed to a single-stranded DNA break by an endonuclease activity such as apurinic/apyrimidinic endonuclease 1 (27) . The single-stranded DNA break attracts poly(ADP-ribose) polymerase 1 or 2 (collectively referred to as PARP), which subsequently poly(ADPribosyl)ates itself and other proteins, leading to the binding of the scaffolding protein XRCC1 and additional proteins required for completion of BER (28) . 
MATERIALS AND METHODS
Cell lines and culture-A2780, OVCAR-3, OVCAR-5, OVCAR-8, and SKOV3ip cells were cultured at 37ÛC in 5% CO 2 with 10% fetal bovine serum (Atlanta Biologicals) in the following media: A2780 and OVCAR-3, RPMI-1640 supplemented with 10 μg/mL insulin (Gibco); OVCAR-5 and OVCAR-8, RPMI-1640 (Mediatech); SKOV3ip, DMEM (Mediatech); and WS1, MEM (Mediatech). OSEtsT/hTERT cells (29) were cultured in 5% CO 2 at 34ÛC in a 1:1 mix of M199:MCDB105 (Sigma) supplemented with 10% fetal bovine serum and 20 μg/ml hygromycin B. For clonogenic assays, the above media were supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin (Mediatech).
OVCAR-3 and WS1 cell lines were obtained from ATCC, which authenticated the lines by short tandem repeat profiling. OVCAR-5 and OVCAR-8 were a gift from Dominic Scudierio (National Cancer Institute). SKOV3ip, A2780, and OSEtsT/hTERT cells were gifts from Viji Shridhar (Mayo Clinic) and were genotyped shortly before acquisition.
Every 3 months, all cell lines were re-initiated from cryopreserved stocks prepared immediately after receipt from the indicated sources. Mechanism-guided identification of novel drug combination 8 immunoblotting and immunostaining were performed as described (35, 36) (Fig. 1D ), a marker of DNA damage (38) . Taken together, these results demonstrate that both fluoropyrimidines induce DNA damage and activate the ATM and ATR checkpoint signaling pathways.
Materials-Reagents

RESULTS
5-FU and FdUrd activate checkpoint kinases-Previously
ATR but not ATM is important for FdUrd toxicity-Activation of Chk1 and Chk2
suggests that signaling through ATM and/or ATR, both of which affect the survival of cells treated with multiple distinct genotoxins, may influence the toxicity of these agents.
To assess how these kinases impact 5-FU and FdUrd cytotoxicity, OVCAR-8 cells were transfected with siRNAs that deplete ATM (ATM-1) and ATR (ATR-2). These siRNAs showed no cytotoxicity on their own (ATM siRNA-transfected cell plating efficiency = 106.7 ± 4.3%, mean ± SEM, n = 4; ATR-siRNA transfected cell plating efficiency = 100.3 ± 11.8%, n = 5, compared to luciferase siRNA-transfected cells) and did not affect formation of the FdUMP-thymidylate synthase complex, indicating that they did not alter uptake and/or metabolism of 5-FU and FdUrd (Fig. S1A) . Surprisingly, neither ATM nor ATR depletion sensitized either cell line to 5-FU ( Fig. 2A-B , left panels), demonstrating that even though the ATM and ATR pathways are activated, they do not protect these cell lines from 5-FU. Far different results were seen with FdUrd. Whereas ATM depletion (which sensitized to ionizing radiation, Fig. S1B ) had no effect on FdUrd cytotoxicity, ATR depletion profoundly sensitized the cells to FdUrd ( Fig. 2A-B , right panels; see (Fig. 4A, left panel) , followed by continuous treatment with the PARP inhibitor.
No such increase in cytotoxicity was seen with 5-FU and PARP inhibitor co-exposure (Fig. 4A, right panel) . 
with FdUrd or 5-FU plus ABT-888 for the duration of the clonogenic assay (8 d). As shown in Fig. 4B , the concentrations of 5-FU and FdUrd that inhibited proliferation by 50% (IC 50 ) were reduced when cells were continuously exposed to these agents, and were similar to the IC 50 s of colon cancer cell lines that have been extensively studied with these fluoropyrmidines (Fig. S3) . Importantly, using this exposure paradigm, ABT-888 also potentiated the effects of FdUrd but not 5-FU in OVCAR-8 ( Fig. 4B ) and SKOV3ip cells (Fig. S4A) . Further experiments showed that even when the clonogenic assays were performed with dialyzed fetal bovine serum, which lacks thymidine and therefore enhances 5-FU's DNA-directed cytotoxicity (39), ABT-888 still did not increase cell killing by 5-FU (Fig. S4B) , further demonstrating that 5-FU does not exert its antiproliferative effects by causing DNA damage in these cells. Additionally, as was seen with the siRNAs employed earlier, treatment with the PARP inhibitor ABT-888 did not alter formation of the FdUMP-thymidylate synthase complex in response to treatment with 5-FU and FdUrd (Fig. S4C) .
Given that cells treated continuously with 3 μM ABT-888 had modestly reduced survival compared to vehicle-treated control cells, we next asked whether the cytotoxicity of ABT-888 and FdUrd was synergistic. OVCAR-8 cells were treated with increasing concentrations of FdUrd plus the indicated concentrations of ABT-888 for 24 h (Fig. 4C,   left panel) . After washing, the initial concentrations of ABT-888 were then re-added to the cultures, which were incubated until colonies formed. From these data, we conducted a formal analysis of synergy using the median effect method of Chou and Talalay (40) , assuming that the agents were mutually exclusive. This analysis revealed that the Mechanism-guided identification of novel drug combination 13 combination indices for all the data points were far below 1 (Fig. 4C, right 
ABT-888 prevents recovery from FdUrd-induced cell cycle arrest and promotes FdUrd-
induced apoptosis-To further understand the effects of these agents on cells, we examined how ABT-888 alone, FdUrd alone, and the combination of these two agents (FdUrd+ABT-888) influenced the cell cycle of OVCAR-8 cells. Identical culture plates were exposed for 24 h to ABT-888 alone, FdUrd alone, or the combination (FdUrd+ABT-888), washed, and re-fed with medium or with medium containing ABT-888 (for cells that were initially exposed to ABT-888). Plates were then harvested immediately (0 h) or after incubation for an additional 24 h or 48 h. ABT-888 alone had no effect on the cell cycle at any time point (Fig. 5A) . In contrast, 24-h exposure to Fig. 4 , ABT-888 was present during and after the FdUrd exposure period. However, it was unclear when ABT-888 exposure would most effectively synergize with FdUrd. We therefore compared a series of FdUrd and ABT-888 exposure schemes (Fig. 5C ). Modestly increased cytotoxicity was observed when OVCAR-8 cells were exposed to FdUrd and ABT-888 simultaneously for 24 h (Sequence II), compared to FdUrd alone (Sequence I) (Fig. 5D) . Similarly, exposure to FdUrd alone for 24 h followed by continuous incubation with ABT-888 modestly increased cytotoxicity over FdUrd alone (Sequence III). In contrast, the most robust killing was seen with Sequences IV and V, in which cells were simultaneously exposed to FdUrd and ABT-888, followed by continuous ABT-888 treatment after FdUrd removal. (Fig. 6A) . Formal analyses of synergy showed that this killing was synergistic across a wide range of concentrations in the A2780, OVCAR3, and SKOV3ip cells (Fig.   S5A ). In contrast, ABT-888 did not alter the cytotoxicity of FdUrd in OSEtsT/hTERT (29) , which are immortalized, non-transformed ovarian surface epithelial cells, or in WS1 cells (Fig. 6B) , normal human fibroblasts that undergo a limited number of replications (42) .
ABT-888 is most effective when present during and after the FdUrd exposure-For the experiments shown in
Comparison of FdUrd plus ABT-888 to other chemotherapy plus ABT-888
combinations-PARP inhibition has been reported to sensitize tumor cells to multiple chemotherapy agents (28) . We therefore evaluated the relative ability of ABT-888 to sensitize to various therapies that are used in the treatment of ovarian cancer. Consistent with published results, ABT-888 sensitized OVCAR-8 cells to the topoisomerase I poison, topotecan (Fig. 7)(28) . Similarly, ABT-888 modestly increased the antiproliferative effect of the nitrogen mustard melphalan. In contrast, ABT-888 did not sensitize to the platinating agents, cisplatin, oxaliplatin, carboplatin; the anthracycline antibiotic doxorubicin; the nucleoside analog gemcitabine; the topoisomerase II poison etoposide; or the antimitotic agent vinorelbine (Fig. 7 and Fig. S5B ). As a control we also assessed the effects of ABT-888 on temozolomide, an alkylating agent that induces 
Mechanism-guided identification of novel drug combination 16 lesions repaired by BER (43) . Notably, due to the profound sensitizing effect of ABT-888 to temozolomide (28) , multiple clinical trials combining ABT-888 with temozolomide are now underway (44). In this head-to-head comparison, ABT-888 sensitized these cells to FdUrd as effectively as it sensitized to temozolomide (Fig. 7, compare upper left panel to lower right panel). ATM alone, or even simultaneous ATM and ATR depletion did not sensitize either cell line to 5-FU. Given that in the same experiments the ATM depletion effectively sensitized to ionizing radiation (Fig. S1B) and that ATR depletion dramatically sensitized to FdUrd ( Fig. 2A-B) , it is unlikely that our results are explained by insufficient depletion of these checkpoint kinases. Instead, our findings suggest that unknown molecular differences among these cell lines may underlie these divergent findings. 
DISCUSSION
